Cost-utility analysis of a national project to reduce hypertension in Israel
- PDF / 211,503 Bytes
- 11 Pages / 610 x 792 pts Page_size
- 16 Downloads / 145 Views
BioMed Central
Open Access
Research
Cost-utility analysis of a national project to reduce hypertension in Israel Chaim Yosefy*1, Gary Ginsberg2, Reuven Viskoper1, Dror Dicker3 and Dov Gavish4 Address: 1The Israeli Forum for Prevention of Cardiovascular Disease, Barzilai Medical Center Campus Ashkelon, Ben-Gurion University, Israel, 2Department of Medical Technology Assessment, Ministry of Health, Israel, 3Department of Internal Medicine D, Hasharon Medical Center, Petach-Tikva, Tel-Aviv University, Israel and 4Department of Internal Medicine A, Wolfson Medical Center, Holon, Tel-Aviv University, Israel Email: Chaim Yosefy* - [email protected]; Gary Ginsberg - [email protected]; Reuven Viskoper - [email protected]; Dror Dicker - [email protected]; Dov Gavish - [email protected] * Corresponding author
Published: 28 November 2007 Cost Effectiveness and Resource Allocation 2007, 5:16
doi:10.1186/1478-7547-5-16
Received: 9 January 2007 Accepted: 28 November 2007
This article is available from: http://www.resource-allocation.com/content/5/1/16 © 2007 Yosefy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program. Methods: Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs. Results: Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality. Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million. Conclusion: The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.
Background Cardiovascular (CV) risk factors such as hypertension, hyperlipidemia and diabetes, are insufficiently managed, according to current guidelines [1]. This mismanagement occurs in spite of the accepted fact that reaching the recommended target goals of the various guidelines is an
Data Loading...
